Crescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 Years

LAVAL, Quebec -- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities, today announced the signing of an amendment to its contract manufacturer supply agreement (the “Amended Agreement”) with its largest CMO client (the “Client”), a global skin care company. The Amended Agreement expands the existing partnership between Crescita and the Client and is the result of ongoing discussions since the Company announced uncertainty in its CMO pipeline in November 2023, causing the cancellation of certain purchase orders by the Client. Read More